# Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110

> **NCT00631800** · PHASE2 · COMPLETED · sponsor: **Biosynexus Incorporated** · enrollment: 88 (actual)

## Conditions studied

- Staphylococcal Sepsis

## Interventions

- **DRUG:** Pagibaximab (formerly BSYX-A110)

## Key facts

- **NCT ID:** NCT00631800
- **Lead sponsor:** Biosynexus Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2004-03
- **Final completion:** 2004-11
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2008-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00631800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00631800, "Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity Study in VLBW Neonates of BSYX-A110". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00631800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*